Glycobiology and Extracellular Matrices
The Non-phagocytic Route of Collagen Uptake: A DISTINCT DEGRADATION PATHWAY*

https://doi.org/10.1074/jbc.M110.208033Get rights and content
Under a Creative Commons license
open access

The degradation of collagens, the most abundant proteins of the extracellular matrix, is involved in numerous physiological and pathological conditions including cancer invasion. An important turnover pathway involves cellular internalization and degradation of large, soluble collagen fragments, generated by initial cleavage of the insoluble collagen fibers. We have previously observed that in primary mouse fibroblasts, this endocytosis of collagen fragments is dependent on the receptor urokinase plasminogen activator receptor-associated protein (uPARAP)/Endo180. Others have identified additional mechanisms of collagen uptake, with different associated receptors, in other cell types. These receptors include β1-integrins, being responsible for collagen phagocytosis, and the mannose receptor. We have now utilized a newly developed monoclonal antibody against uPARAP/Endo180, which down-regulates the receptor protein level on treated cells, to examine the role of uPARAP/Endo180 as a mediator of collagen internalization by a wide range of cultured cell types. With the exception of macrophages, all cells that proved capable of efficient collagen internalization were of mesenchymal origin and all of these utilized uPARAP/Endo180 for their collagen uptake process. Macrophages internalized collagen in a process mediated by the mannose receptor, a protein belonging to the same protein family as uPARAP/Endo180. β1-Integrins were found not to be involved in the endocytosis of soluble collagen, irrespectively of whether this was mediated by uPARAP/Endo180 or the mannose receptor. This further distinguishes these pathways from the phagocytic uptake of particulate collagen.

Cell Surface Protein
Cysteine Protease
Endocytosis
Extracellular Matrix
Fibroblast
Integrin
Matrix Metalloproteinase (MMP)
Protein Turnover
Blocking Antibody
Collagen Degradation

Cited by (0)

*

This work was supported, in whole or in part, by the National Institutes of Health NIDCR Intramural Research Program (to A. M. and T. H. B.), the Danish Cancer Society, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Lundbeck Foundation, the Danish National Research Foundation (Danish-Chinese Center for Proteases and Cancer), European Community's Seventh Framework Programme FP7/2007–2011 Grant 201279 (to N. B.), grants from the Lundbeck Foundation and the “Grosserer Alfred Nielsen og Hustrus” foundation (to L. H. E.), the Copenhagen University Hospital (to D. H. M. and H. J. J.), and the University of Copenhagen, Faculty of Science (to S. I.).

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

1

Present address: LEO Pharma, Ballerup, Denmark.